AVALYN PHARMACEUTICALS Stock Price, News & Analysis
Company Description
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for serious, rare respiratory diseases. The company focuses on pulmonary fibrosis and other interstitial lung diseases, including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Its common stock is listed on the Nasdaq Global Select Market under the ticker symbol AVLN.
Avalyn's pipeline is built around inhaled formulations of established antifibrotic drug classes. Its lead programs include AP01, an inhaled formulation of pirfenidone, and AP02, an inhaled formulation of nintedanib. The company is developing these candidates for pulmonary fibrosis indications where treatment is directed at lung tissue affected by progressive scarring and impaired respiratory function.
The company's development model centers on targeted delivery of antifibrotic therapy through inhalation. Avalyn's research activities include clinical studies, quantitative lung imaging, patient-reported quality-of-life measures, supportive care research, and work on how patients and caregivers experience inhaled treatment. Company news has also described the use of high-resolution computed tomography imaging in AP01 research and the evaluation of AP01 delivery and supportive care experiences in pulmonary fibrosis.
Avalyn reports one operating and reportable segment: the business of developing and commercializing targeted therapies for rare lung diseases. As a clinical-stage biopharmaceutical company, its operating activities are concentrated on drug development, clinical program execution, product development, medical research, and preparations associated with potential commercialization of respiratory therapies.
Avalyn became a Nasdaq-listed public company following the closing of its initial public offering of common stock. Its public-company profile includes capital-structure matters related to its listed shares, governance updates related to its board and leadership structure, and operating updates tied to its AP01 and AP02 programs.
Stock Performance
AVALYN PHARMACEUTICALS (AVLN) stock last traded at $29.84, down 0.39% from the previous close. Over the past 12 months, the stock has gained 1.2%. At a market capitalization of $1.3B, AVLN is classified as a small-cap stock with approximately 41.8M shares outstanding.
AVLN Rankings
Latest News
AVALYN PHARMACEUTICALS has 7 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 2 with negative movement. Key topics include acquisition, IPO, offering, management. View all AVLN news →
SEC Filings
AVALYN PHARMACEUTICALS has filed 5 recent SEC filings, including 2 Form SCHEDULE 13D, 2 Form SCHEDULE 13G, 1 Form 4. The most recent filing was submitted on May 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AVLN SEC filings →
Insider Radar
Insider buying activity at AVALYN PHARMACEUTICALS over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Poster session P60/P68
AVALYN PHARMACEUTICALS has 1 upcoming scheduled event. The next event, "Poster session P60/P68", is scheduled for May 18, 2026 (tomorrow). Investors can track these dates to stay informed about potential catalysts that may affect the AVLN stock price.
Short Interest History
Days to Cover History
AVLN Company Profile & Sector Positioning
AVALYN PHARMACEUTICALS (AVLN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #1,603 among all tracked companies.